NBIX · Neurocrine Biosciences Inc
$180.79
-2.04 (-1.12%)
At close · Jul 29
Earnings today
Market Cap
$18.18B
Shares
100.55M
Neurocrine Biosciences Inc Earnings Call Transcripts
Every quarterly earnings call for Neurocrine Biosciences Inc (NBIX) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲31%
$387.90M
$68.50M
'22 Q3
22-11-01
▲32.1%
$412.00M
$89.00M
'22 Q4
23-02-06
▲35.4%
$420.40M
−$76.60M
'23 Q1
23-05-03
▲19.7%
$452.70M
$95.50M
'23 Q2
23-08-01
▲28.6%
$498.80M
$83.10M
'23 Q3
23-10-31
▲25%
$515.20M
$147.70M
'23 Q4
24-02-07
▲22.6%
$515.30M
$43.40M
'24 Q1
24-05-01
▲30.4%
$590.20M
$65.00M
'24 Q2
24-08-01
▲24.7%
$622.10M
$129.80M
'24 Q3
24-10-30
▲21.8%
$627.70M
$103.10M
'24 Q4
25-02-06
▲11.1%
$572.60M
$7.90M
'25 Q1
25-05-05
▲16.5%
$687.50M
$107.50M
'25 Q2
25-07-30
▲27.8%
$794.90M
$209.50M
'25 Q3
25-10-28
▲28.3%
$805.50M
$153.70M
'25 Q4
26-02-11
LATEST
▲42.2%
$814.50M
$197.90M
'26 Q1
26-05-05
Earnings call
FY26 · Q2
2026-07-30
Neurocrine Biosciences Conference Call and Webcast of Q2 2026 Financial Results
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-05-26
Neurocrine Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-26
Neurocrine Biosciences to Present at the William Blair 46th Annual Growth Stock Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-05
Neurocrine Biosciences Inc Q1 FY2026 Earnings Call
Confident tone
INGREZZA commercial performance and TD market opportunity
R&D pipeline and upcoming data readouts
Payer seasonality and reimbursement dynamics
Revenue
$814.50M
▲ 42.2% YoY Diluted EPS
$1.91
▲ 2287.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-11
Neurocrine Biosciences Inc Q4 FY2025 Earnings Call
Confident tone
CRENESSITY launch and CAH market development
U.S. focus and European business divestiture
INGREZZA commercial performance
Revenue
$805.50M*
▲ 28.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-28
Neurocrine Biosciences Inc Q3 FY2025 Earnings Call
Confident tone
INGREZZA commercial momentum
CRENESSITY launch
Clinical pipeline advancement
Revenue
$794.90M
▲ 27.8% YoY Diluted EPS
$2.04
▲ 64.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-30
Neurocrine Biosciences Inc Q2 FY2025 Earnings Call
Confident tone
CRENESSITY launch
INGREZZA commercial performance
Pipeline and R&D Day
Revenue
$687.50M
▲ 16.5% YoY Diluted EPS
$1.06
▲ 68.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-05
Neurocrine Biosciences Inc Q1 FY2025 Earnings Call
Confident tone
INGREZZA Commercial Performance
CRENESSITY Launch
Pipeline and R&D
Revenue
$572.60M
▲ 11.1% YoY Diluted EPS
$0.08
▼ 81% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-06
Neurocrine Biosciences Inc Q4 FY2024 Earnings Call
Revenue
$627.70M*
▲ 21.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-30
Neurocrine Biosciences Inc Q3 FY2024 Earnings Call
Confident tone
Crinecerfont launch preparation for CAH
INGREZZA commercial performance and TD market opportunity
Pipeline progression - NBI-'845 and NBI-'568
Revenue
$622.10M
▲ 24.7% YoY Diluted EPS
$1.24
▲ 51.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Neurocrine Biosciences Inc Q2 FY2024 Earnings Call
Confident tone
Crinecerfont Launch Preparation
INNGREZZA Commercial Momentum
INNGREZZA Lifecycle and Formulation Expansion
Revenue
$590.20M
▲ 30.4% YoY Diluted EPS
$0.63
▼ 33.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-01
Neurocrine Biosciences Inc Q1 FY2024 Earnings Call
Confident tone
Crinecerfont NDA and launch prep
INGREZZA franchise growth
NBI-845 (AMPA) in major depressive disorder
Revenue
$515.30M
▲ 22.6% YoY Diluted EPS
$0.42
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-07
Neurocrine Biosciences Inc Q4 FY2023 Earnings Call
Confident tone
Ingrezza franchise growth
2024 financial guidance and SG&A leverage
R&D pipeline expansion
Revenue
$515.20M*
▲ 25% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-10-31
Neurocrine Biosciences Inc Q3 FY2023 Earnings Call
Revenue
$498.80M
▲ 28.6% YoY Diluted EPS
$0.82
▲ 18.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-01
Neurocrine Biosciences Inc Q2 FY2023 Earnings Call
Revenue
$452.70M
▲ 19.7% YoY Diluted EPS
$0.95
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-03
Neurocrine Biosciences Inc Q1 FY2023 Earnings Call
Revenue
$420.40M
▲ 35.4% YoY Diluted EPS
$-0.79
▼ 664.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-06
Neurocrine Biosciences Inc Q4 FY2022 Earnings Call
Revenue
$412.00M*
▲ 32.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-01
Neurocrine Biosciences Inc Q3 FY2022 Earnings Call
Revenue
$387.90M
▲ 31% YoY Diluted EPS
$0.69
▲ 200% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Neurocrine Biosciences Inc Q2 FY2022 Earnings Call
Revenue
$378.20M
▲ 30.9% YoY Diluted EPS
$-0.18
▼ 141.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
Neurocrine Biosciences Inc Q1 FY2022 Earnings Call
Revenue
$310.60M
▲ 31.3% YoY Diluted EPS
$0.14
▼ 57.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-01-06
Neurocrine Biosciences Inc Q4 FY2021 Earnings Call
Revenue
$312.00M*
▲ 25.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-01
Neurocrine Biosciences Inc Q3 FY2021 Earnings Call
Revenue
$296.00M
▲ 14.5% YoY Diluted EPS
$0.23
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-03
Neurocrine Biosciences Inc Q2 FY2021 Earnings Call
Revenue
$288.90M
▼ 4.5% YoY Diluted EPS
$0.43
▼ 46.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-05
Neurocrine Biosciences Inc Q1 FY2021 Earnings Call
Revenue
$236.60M
▼ 0.2% YoY Diluted EPS
$0.33
▼ 15.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-01-08
Neurocrine Biosciences Inc Q4 FY2020 Earnings Call
Revenue
$247.90M
▲ 1.6% YoY Diluted EPS
$3.58
▲ 922.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-09
Neurocrine Biosciences Inc Q3 FY2020 Earnings Call
Revenue
$258.50M
▲ 16.4% YoY Diluted EPS
$-0.62
▼ 210.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-06-30
Neurocrine Biosciences Inc Q2 FY2020 Earnings Call
Revenue
$302.40M
▲ 64.8% YoY Diluted EPS
$0.81
▲ 50% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-06
Neurocrine Biosciences Inc Q1 FY2020 Earnings Call
Revenue
$237.10M
▲ 71.3% YoY Diluted EPS
$0.39
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-05
Neurocrine Biosciences Inc Q4 FY2019 Earnings Call
Revenue
$244.10M
▲ 85.6% YoY Diluted EPS
$0.35
▲ 84.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–29 of 29 earnings calls
Key facts
CIK
914475
CUSIP
64125C109
13F (30d)
255 filings
228 filers
Visit website
Investor relations